---
schema_version: "secwatch.filing_event.v1"
accession: "0001823239-24-000093"
form_type: "8-K"
ticker: "MRVI"
cik: "0001823239"
company_name: "MARAVAI LIFESCIENCES HOLDINGS, INC."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:52:39.028257+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Maravai Q2 revenue up 6.5% to $73.4M, net loss $14.5M; reaffirms FY2024 guidance

## Summary
- Q2 revenue $73.4M (+6.5% YoY); Nucleic Acid Production +9.8%, Biologics Safety Testing -4.7%.
- Net loss $(14.5)M vs $(11.9)M prior year; Adjusted EBITDA $16.9M up from $9.1M.
- H1 2024 revenue $137.6M (-7% YoY); net loss $(37.2)M vs $(13.3)M.
- Reaffirms FY2024 revenue guidance $265M-$285M.
- Business updates: TriLink-Johns Hopkins collaboration, Flanders facilities milestones, new product launches.

## SEC filing metadata
- accession: 0001823239-24-000093
- form_type: 8-K
- ticker: MRVI
- cik: 0001823239
- company_name: MARAVAI LIFESCIENCES HOLDINGS, INC.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1823239/000182323924000093/0001823239-24-000093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1823239/000182323924000093/mrvi-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001823239-24-000093
- JSON: https://secwatch.observer/filing/0001823239-24-000093.json
- Plain text: https://secwatch.observer/filing/0001823239-24-000093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.